Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes

@inproceedings{Spindelboeck2016TripleTW,
  title={Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes},
  author={Walter Spindelboeck and Angela Horvath and Monika Tawdrous and Bianca Schmerb{\"o}ck and Gabriele Zettel and Andreas Posch and Andrea Streit and Petra Jurse and Sandra Lemesch and Martin Horn and Gerit Wuensch and Philipp Stiegler and Rudolf E. Stauber and Bettina Leber and Vanessa Stadlbauer},
  booktitle={PloS one},
  year={2016}
}
First-generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection (CHC), but substantially increased rates of viral clearance are offset by increased rates of infection and infection-associated deaths, especially of patients with advanced liver disease. We aimed to assess whether first generation protease inhibitors interfere with neutrophil function. We included 108 consecutive, retrospective CHC patients and 44 consecutive, prospective CHC… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes .
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes .
Neutrophil phagocytosis , oxidative burst , elastase and diamine oxidase levels during 12 weeks of triple ( n = 23 ) or dual therapy ( n = 21 ) were studied in the prospective part .
Neutrophil phagocytosis decreased to 40% of baseline with addition of protease inhibitors to P / R but recovered 6 months after end of treatment .
Neutrophil phagocytosis , oxidative burst , elastase and diamine oxidase levels during 12 weeks of triple ( n = 23 ) or dual therapy ( n = 21 ) were studied in the prospective part .
Neutrophil phagocytosis decreased to 40% of baseline with addition of protease inhibitors to P / R but recovered 6 months after end of treatment .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
First - generation HCV protease inhibitors represent a milestone in antiviral therapy for chronic hepatitis C infection ( CHC ) , but substantially increased rates of viral clearance are offset by increased rates of infection and infection - associated deaths , especially of patients with advanced liver disease .
All Topics